Increased Uptake of Neoadjuvant Chemotherapy Does Not Explain Trend Toward Improved Survival in Advanced Ovarian Cancer

Web Exclusives - Ovarian Cancer

Median overall survival (OS) improved by more than 6 months between 2004 and 2016 for women treated for advanced epithelial ovarian cancer.

Increased use of neoadjuvant chemotherapy during this period was not associated with a change in median survival trend, according to Anne T. Knisely, MD, PGY-3 Resident, Obstetrics and Gynecology, New York-Presbyterian/Columbia University Medical Center, New York City, and colleagues, and published in JAMA Network Open (Knisely AT, et al. JAMA Netw Open. 2020;3:32017517).

The investigators’ retrospective cohort study used the National Cancer Database to identify 72,171 women who received treatment (ie, chemotherapy, surgery, or both) for stage IIIC or IV epithelial ovarian cancer and were diagnosed between January 1, 2004, and December 31, 2016. Mean age of the cohort was 63.0 years. Survival was measured from the time of diagnosis to death or last follow-up.

A total of 53,021 women were treated with primary cytoreductive surgery (73.5%) and 19,150 with neoadjuvant chemotherapy (26.5%) throughout the study period. From 2004 to 2006, 17.6% of participants received neoadjuvant chemotherapy, a rate that accelerated by 10.3% per year starting in 2011 (change of trend, P = .01).

Approximately 75% of the women treated with primary cytoreductive surgery had serious adenocarcinoma compared with approximately 25% treated with neoadjuvant chemotherapy.

The frequency of primary chemotherapy increased by 7.9% per year from 2006 to 2011 (change of trend, P <.001). By 2016, 45.1% of patients received chemotherapy as their initial treatment.

Median OS increased from 31.1 months in 2004 to 37.8 months in 2013. The increased uptake of neoadjuvant chemotherapy over the study period was not associated with a change in median survival trend, which increased by 2.1% per year (change of trend, P = .37). When the analysis was restricted to the subgroup of patients with high-grade serous carcinoma, results were similar: the increase in the use of neoadjuvant chemotherapy starting in 2006 was not associated with a change of trend in median survival, which increased by 2.0% per year (change of trend, P = .21).

Related Items
2020 Year in Review - Ovarian Cancer
2020 Year in Review - Ovarian Cancer published on November 28, 2020 in Ovarian Cancer
Telehealth Coverage Expanded During the COVID-19 Pandemic
Web Exclusives published on November 19, 2020 in Ovarian Cancer
Trabectedin Added to Pegylated Doxorubicin May Be Viable Treatment for Recurrent Ovarian Cancer But Platinum Remains Standard of Care
Web Exclusives published on November 19, 2020 in Ovarian Cancer
NORA Clinical Trial Confirms Efficacy of Individualized Niraparib Starting Dose to Treat Platinum-Sensitive Ovarian Cancer
Web Exclusives published on November 19, 2020 in Ovarian Cancer
Platinum-Based Chemotherapy Following Progression on PARP Inhibitor Maintenance Yields Greatest Benefit in Advanced Ovarian Cancer with Platinum-Free Interval >12 Months
Web Exclusives published on November 19, 2020 in Ovarian Cancer
ASCO Guidelines Support PARP Inhibitor Use in Maintenance and Recurrent Setting of Advanced Ovarian Cancer
Web Exclusives published on October 13, 2020 in Ovarian Cancer
Niraparib Efficacy in Advanced Ovarian Cancer Extends to All Biomarker Subgroups
Web Exclusives published on October 13, 2020 in Ovarian Cancer
Olaparib/Bevacizumab as First-Line Maintenance Reduces Risk for Progression or Death in Patients with Advanced Ovarian Cancer
Web Exclusives published on October 13, 2020 in Ovarian Cancer
Online Delivery of Genetic Services: No Increase in Cancer Risk Distress versus Telephone Counseling
Web Exclusives published on October 13, 2020 in Ovarian Cancer
Phase 2 OVARIO Update: Promising Survival Rates in Patients with Advanced Ovarian Cancer Treated with Niraparib plus Bevacizumab Maintenance
Web Exclusives published on September 15, 2020 in Ovarian Cancer
Last modified: November 19, 2020